Trial Search Results

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Bristol-Myers Squibb

Collaborator: EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib

Stanford Investigator(s):

Intervention(s):

  • Drug: Dasatinib

Phase:

Phase 2

Eligibility


For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

   - Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)

   - Age >1 year and < less than 18 years old

   - Induction chemotherapy ≤ 14 days according to institutional standard of care

   - Adequate liver, renal and cardiac function

Exclusion Criteria:

   - Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor

   - Extramedullary involvement of the testicles

   - Active systemic bacterial, fungal or viral infection

   - Down syndrome

Ages Eligible for Study

1 Year - 17 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pediatric Hematology/Oncology
650-723-5535
Not Recruiting